# Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

> **NCT04471415** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dracen Pharmaceuticals, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Advanced Solid Tumor
- Non Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** DRP-104
- **BIOLOGICAL:** atezolizumab

## Key facts

- **NCT ID:** NCT04471415
- **Lead sponsor:** Dracen Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-31
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-03-28
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Company decision to closing study and discontinue further patient enrollment.
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471415, "Study to Investigate DRP-104 in Adults With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04471415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*